Skip to main content

Perceptive Advisors — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

225
Companies
$29.6B
Total invested
$156.7M
Avg. check
19
Industries
Biotechnology 20Health Care 14Medical 10Life Science 8Therapeutics 8Pharmaceutical 6+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 25–48 of 225
4D Molecular Therapeutics
June 2026

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Biotechnology · Emeryville$200.0M Post-IPO Debt
Black Diamond Therapeutics
June 2023

Black Diamond Therapeutics is a medical company focused on analyzing genetically defined cancers.

Biotechnology · Cambridge$75.0M Post-IPO Equity
Cerebral Therapeutics
June 2022

Cerebral Therapeutics is a clinical-stage pharmaceutical company.

Biotechnology · Aurora$40.0M Series C
Nuvation Bio
June 2026

Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.

Biotechnology · New York$250.0M Post-IPO Debt
Absci
June 2026

Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins

Artificial Intelligence (AI) · Vancouver$100.0M Post-IPO Equity
Scribe Therapeutics
June 2026

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.

Biotechnology · Alameda$25.0M Grant
Marea Therapeutics
June 2024

Marea is a biotechnology company that develops therapies and medications for the treatment of cardioendocrine illness patients.

Biotechnology · San Francisco$190.0M Series B
Neuron23
June 2026

Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.

Health Care · San Francisco$2.5M Grant
SOPHiA GENETICS
June 2026

SOPHiA GENETICS is a biotechnology firm that aims to support healthcare professionals by maximizing the power of data-driven medicine.

Artificial Intelligence (AI) · Boston$57.5M Post-IPO Equity
Zentalis Pharmaceuticals
June 2023

Zentalis is a pharmaceutical company focused on developing clinical therapeutics for cancer patients.

Biopharma · New York$235.5M Post-IPO Equity
Mereo Biopharma
June 2024

Mereo is a new UK-based speciality biopharmaceutical company.

Biopharma · London$50.0M Post-IPO Equity
Orchestra BioMed
May 2026

Orchestra BioMed is a biomedical innovation company that provides high-impact solutions for large unmet needs in procedure-based medicine.

Biotechnology · New Hope$35.0M Post-IPO Debt
Apogee Therapeutics
May 2026

Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders.

Biotechnology · San Francisco$1.3B Post-IPO Debt
A-Alpha Bio
May 2024

A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions.

Biotechnology · Seattle$14.5M Grant
Relay Therapeutics
May 2026

Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.

Biotechnology · Cambridge$275.0M Post-IPO Equity
CinDome Pharma
May 2024

CinDome Pharma provides treatment for the millions of people living with the devastating impact of chronic gastroparesis.

Health Care · Cincinnati$40.0M Series B
Imperative Care
March 2026

Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.

Health Care · Campbell$100.0M Convertible Note
Alto Neuroscience
March 2026

Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.

Artificial Intelligence (AI) · Los Altos$120.0M Post Ipo Equity
Outlook Therapeutics
March 2026

Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations.

Biopharma · Iselin$18.4M Post Ipo Debt
Solid Biosciences
March 2026

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Biotechnology · Charlestown$240.0M Post Ipo Equity
Beam Therapeutics
February 2026

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Biotechnology · Cambridge$100.0M Post Ipo Debt
Talkiatry
February 2026

Talkiatry provides virtual mental healthcare services covered by insurance, connecting patients with licensed psychiatrists.

Health Care · New York$210.0M Series D
Xilio Therapeutics
February 2026

Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.

Biopharma · Waltham$40.0M Post Ipo Equity
Nautilus Biotechnology
January 2026

Nautilus Biotechnology is a life sciences company that develops a platform for analyzing and quantifying the human proteome.

Biotechnology · San Carlos$1.6M Grant

Where Perceptive Advisors invests

Biotechnology20
Health Care14
Medical10
Life Science8
Therapeutics8
Pharmaceutical6

About Perceptive Advisors's portfolio

How many companies has Perceptive Advisors invested in?▸

Perceptive Advisors has invested in 225 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Perceptive Advisors invest in?▸

Perceptive Advisors's top investment sectors include Biotechnology, Health Care, Medical, Life Science, Therapeutics. The firm invests across 19 different industry categories.

What is Perceptive Advisors's largest investment?▸

Among tracked funding rounds, Apogee Therapeutics received $1.3B in a Post-IPO Debt round. Perceptive Advisors's total known invested capital is $29.6B.

What is the average investment size for Perceptive Advisors?▸

Perceptive Advisors's average investment size is $156.7M across its portfolio of 225 companies.

What are Perceptive Advisors's most recent investments?▸

Recent Perceptive Advisors portfolio additions include 4D Molecular Therapeutics, Black Diamond Therapeutics, Cerebral Therapeutics, Nuvation Bio, Absci. These companies were founded in 2020 or later.

Reach the founders behind these 225 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →